Skip to main content
. Author manuscript; available in PMC: 2017 Jan 5.
Published in final edited form as: Urol Oncol. 2012 Jun 19;31(8):1676–1682. doi: 10.1016/j.urolonc.2012.05.007

Fig. 5.

Fig. 5

Lenalidomide augments cell death in vitro with TNF-α but not with FasL. (A) MBT-2 cells were treated as indicated in the figure; 24 hours after treatment, the cells were imaged. Len = lenalidomide, TNF-α and FasL concentrations were 17 ng/ml. (B) The cell death was confirmed by chromatin condensation (because of caspase-3 activation) by staining the cells using live stain Hoechst-33,342. Note the chromatin condensation (arrow heads) in TNF-α treated conditions but not in FasL treated conditions. (Color version of figure is available online.)